Liposoluble vitamins A and E in kidney disease

Table 2 Reported human clinical trials of vitamin E administration in chronic kidney disease subjects

Ref.	n	Dose	Inclusion criteria	Outcome
Mann et al[49]	993	400 IU/d	1.4 ≤ SCr ≤ 2.3 mg/dL. Plus CV disease or DM	Follow-up 4.5 yr. No apparent effect on CV outcomes
Giannini et al[50]	10	1200 IU/d	Type 1 diabetes mellitus plus macroalbuminuria	Reduces markers of oxidative stress. No effect on MA
Khatami et al[51]	60	1200 IU/d	Diabetic nephropathy	Decrease in protein/creatinine ratio. Reduction in inflammatory markers
Boaz et al[52]	196	800 IU/d	Hemodialysis patients	Reduces CV disease
Himmelfarb et al[53]	30	300 IU/d	15 healthy subjects, 15 hemodialysis patients	Reduction on C reactive protein
Bergin et al[54]			Meta-analysis 16 papers	Reduction oxidative stress
Mune et al[55]	40	300 mg/d	Hemodialysis subjects	Improvement in endothelial function

CV: Cardiovascular.